Cargando…

Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension

There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASP...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Robert A., Thompson, A.A. Roger, Billings, Catherine G., Charalampopoulos, Athanasios, Elliot, Charlie A., Hamilton, Neil, Hill, Catherine, Hurdman, Judith, Rajaram, Smitha, Sabroe, Ian, Swift, Andy J., Kiely, David G., Condliffe, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270350/
https://www.ncbi.nlm.nih.gov/pubmed/32108045
http://dx.doi.org/10.1183/13993003.00041-2020
_version_ 1783541889123745792
author Lewis, Robert A.
Thompson, A.A. Roger
Billings, Catherine G.
Charalampopoulos, Athanasios
Elliot, Charlie A.
Hamilton, Neil
Hill, Catherine
Hurdman, Judith
Rajaram, Smitha
Sabroe, Ian
Swift, Andy J.
Kiely, David G.
Condliffe, Robin
author_facet Lewis, Robert A.
Thompson, A.A. Roger
Billings, Catherine G.
Charalampopoulos, Athanasios
Elliot, Charlie A.
Hamilton, Neil
Hill, Catherine
Hurdman, Judith
Rajaram, Smitha
Sabroe, Ian
Swift, Andy J.
Kiely, David G.
Condliffe, Robin
author_sort Lewis, Robert A.
collection PubMed
description There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAH(no-LD) (n=303), and those with minor/mild emphysema or fibrosis were described as IPAH(mild-LD) (n=190). Survival was significantly better in IPAH(no-LD) than in IPAH(mild-LD) (1- and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAH(no-LD) and IPAH(mild-LD), independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D(LCO)), lower exercise capacity and a diagnosis of IPAH(mild-LD) (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAH(no-LD), but not IPAH(mild-LD). A proportion of patients with IPAH(no-LD) had a D(LCO) <45%; these patients had poorer survival than patients with D(LCO) ≥45%, although they demonstrated improved exercise capacity following treatment. The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D(LCO) may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required.
format Online
Article
Text
id pubmed-7270350
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-72703502020-06-09 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Lewis, Robert A. Thompson, A.A. Roger Billings, Catherine G. Charalampopoulos, Athanasios Elliot, Charlie A. Hamilton, Neil Hill, Catherine Hurdman, Judith Rajaram, Smitha Sabroe, Ian Swift, Andy J. Kiely, David G. Condliffe, Robin Eur Respir J Original Articles There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAH(no-LD) (n=303), and those with minor/mild emphysema or fibrosis were described as IPAH(mild-LD) (n=190). Survival was significantly better in IPAH(no-LD) than in IPAH(mild-LD) (1- and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAH(no-LD) and IPAH(mild-LD), independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D(LCO)), lower exercise capacity and a diagnosis of IPAH(mild-LD) (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAH(no-LD), but not IPAH(mild-LD). A proportion of patients with IPAH(no-LD) had a D(LCO) <45%; these patients had poorer survival than patients with D(LCO) ≥45%, although they demonstrated improved exercise capacity following treatment. The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D(LCO) may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required. European Respiratory Society 2020-06-04 /pmc/articles/PMC7270350/ /pubmed/32108045 http://dx.doi.org/10.1183/13993003.00041-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
spellingShingle Original Articles
Lewis, Robert A.
Thompson, A.A. Roger
Billings, Catherine G.
Charalampopoulos, Athanasios
Elliot, Charlie A.
Hamilton, Neil
Hill, Catherine
Hurdman, Judith
Rajaram, Smitha
Sabroe, Ian
Swift, Andy J.
Kiely, David G.
Condliffe, Robin
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title_full Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title_fullStr Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title_full_unstemmed Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title_short Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
title_sort mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270350/
https://www.ncbi.nlm.nih.gov/pubmed/32108045
http://dx.doi.org/10.1183/13993003.00041-2020
work_keys_str_mv AT lewisroberta mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT thompsonaaroger mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT billingscatherineg mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT charalampopoulosathanasios mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT elliotcharliea mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT hamiltonneil mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT hillcatherine mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT hurdmanjudith mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT rajaramsmitha mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT sabroeian mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT swiftandyj mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT kielydavidg mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension
AT condlifferobin mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension